Objectors to Bayer's $7.25B Roundup settlement are trying to remove the case to federal court, arguing they qualify as defendants under removal doctrine.
Opponents of Bayer's $7.25 billion Roundup class action settlement have filed to remove the case from Missouri state court to federal court, setting off a venue battle that could unravel one of the largest mass-tort settlements in American litigation history [1]. The maneuver, which carries significant doctrinal stakes, came as a June 4 opt-out deadline for class members passed [1].
The settlement received preliminary approval from a Missouri state court in March [1]. Objectors are now pursuing removal on the theory that, as parties opposing the deal, they function as effective "defendants" with statutory standing to seek federal jurisdiction, a reading that stretches conventional removal doctrine well beyond its ordinary application [1]. If the transfer succeeds, the case would likely land before U.S. District Judge Vince Chhabria in California, who oversees the federal multidistrict litigation consolidating thousands of Roundup personal-injury claims and has previously criticized the proposed settlement's terms [1][2]. Bayer has announced it will oppose the conditional transfer order [2].
The procedural stakes are substantial. Removal doctrine generally permits defendants, not objectors, to seek transfer to federal court. If a court accepts the objectors' theory, it would expand the class of parties eligible to invoke federal jurisdiction in class action settlements, a result with implications far beyond this case. Counsel Ashley Keller is among the attorneys leading the opposition [1]. Bayer, the German pharmaceutical and agrochemical conglomerate that acquired Monsanto in 2018, has spent years attempting to resolve a litigation wave stemming from claims that glyphosate, the active ingredient in Roundup, causes non-Hodgkin's lymphoma. The $7.25 billion figure represents Bayer's effort to achieve global peace with class members who have not yet filed suit [1].
A parallel track adds further pressure. The Supreme Court is expected to issue a ruling on whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-law failure-to-warn claims against Roundup, a decision that would directly determine the scope of Bayer's remaining litigation exposure regardless of how the venue dispute resolves [1]. An adverse preemption ruling for plaintiffs could render the settlement moot as a liability management vehicle; a favorable one for Bayer could strengthen its hand in resisting further claims. The two proceedings are independent but temporally linked.
Bayer's challenge to the conditional transfer order will likely be the next significant procedural event, with briefing schedules to be set in the coming weeks [2].